Benitec Biopharma Inc. (BNTC) Dividend History

Benitec Biopharma Inc. (BNTC) is a biotechnology company focused on developing gene-based therapeutics. It specializes in innovative DNA-based methods, particularly RNA interference (RNAi) technology, to target genetic and viral diseases. The company's approach aims to leverage gene silencing for therapeutic benefits across various medical conditions.

3940 Trust Way, Hayward, CA, 94545
Phone: (510) 780-0819
Website: https://www.benitec.com

Dividend History

Benitec Biopharma Inc. currently does not pay dividends

Company News

Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference

Benitec Biopharma announced the acceptance of a late-breaking oral abstract for the BB-301 Phase 1b/2a clinical study in Oculopharyngeal Muscular Dystrophy (OPMD) patients. Interim clinical study updates for the first three subjects will be presented at the Muscular Dystrophy Association Clinical and Scientific Conference in March 2025.

GlobeNewswire Inc.
RNA Based Therapeutic Market Size Expected to Reach USD 40.81 Bn by 2034

The global RNA-based therapeutic market is expected to grow from $9.46 billion in 2025 to $40.81 billion by 2034, driven by the rising prevalence of genetic disorders and the demand for personalized medicine. North America and Asia Pacific are the key regional markets.

GlobeNewswire Inc.

Featured Companies: ALNY IONS XLO
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society

Benitec Biopharma reported positive data from two subjects treated with low-dose BB-301 in a Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy (OPMD). The subjects experienced durable, clinically meaningful improvements in swallowing, with one subject achieving a clinically normal swallowing profile.

GlobeNewswire Inc.
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update

Benitec Biopharma reported positive 90-day and 180-day interim clinical data for the first subject dosed with the low-dose of BB-301 in the Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy (OPMD). The company also dosed a second subject and expects to dose a third subject in Q4 2024. Benitec closed a $40 million private placement financing, extending its cash runway through 2025.

GlobeNewswire Inc.
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society

Benitec Biopharma announced that a late-breaking abstract on its BB-301 gene therapy for oculopharyngeal muscular dystrophy (OPMD) has been accepted for oral presentation at the 29th Annual Congress of the World Muscle Society.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 19:54:21 UTC